Hemorrhoid

Thena Natural Wellness Launches Plant-Based Skincare Line for Whole-Body Wellness

Retrieved on: 
Wednesday, February 1, 2023
Rosacea, Acne, Vitamin, Dermatology, Immunity, Ageing, Aromatherapy, Face, Hyperpigmentation, Safety, Antioxidant, Skin, Health, Paraben, Pregnancy, Epidermis, Dermatitis, Scalp, Beauty, Sulfate, Hemorrhoid, Science, Nutrient, Cosmetics

Toronto, Ontario--(Newsfile Corp. - February 1, 2023) - Thena Natural Wellness, an emerging natural skincare company, is proud to announce the launch of their latest line of plant-based, gentle, high-performing products that help achieve whole-body wellness .

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - February 1, 2023) - Thena Natural Wellness, an emerging natural skincare company, is proud to announce the launch of their latest line of plant-based, gentle, high-performing products that help achieve whole-body wellness .
  • Thena Natural Wellness's goal is to provide the best natural skincare products that bridge the gap between beauty and well-being.
  • Thena offers both non-fragranced as well as products combining skincare with aromatherapy for holistic healing, skin nourishment and anti-aging .
  • Thena Natural Wellness's approach to formulation is focused on maintaining, restoring, and strengthening the function of the skin barrier .

InventHelp Inventor Develops New Hemorrhoid Relief Product (BEC-247)

Retrieved on: 
Monday, December 26, 2022
DEPT, Pain, Sale, Multimedia, Hemorrhoid, Publishing

The patent-pending invention provides effective relief from the discomfort of hemorrhoids.

Key Points: 
  • The patent-pending invention provides effective relief from the discomfort of hemorrhoids.
  • The invention features a practical and convenient design that is easy to transport and use so it is ideal for individuals who experience hemorrhoids.
  • The original design was submitted to the Boston sales office of InventHelp.
  • 21-BEC-247, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Retrieved on: 
Thursday, December 1, 2022
Itch, IL-2R, COVID-19, Protein, Immune system, MF, Haematopoietic system, Food, Pivotal, Pain, NHL, Mycosis fungoides, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Malignancy, Regulation, Drug Quality and Security Act, Hemorrhoid, Annual report, CGMP, PTCL, Interleukin, Diphtheria, Disease, Patent, Peripheral T-cell lymphoma, SS, Cancer, Research, Quality of life, Woman, Lymph, Immunotherapy, Cutaneous lymphoma, PDUFA, FDA, BLA, Pharmaceutical industry, Vaccine, CTCL, Citius, Altius, Fortius

CRANFORD, N.J., Dec. 1, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's Biologics License Application (BLA) for denileukin diftitox ("I/ONTAK" or "E7777"), an engineered IL-2-diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL). I/ONTAK is a purified and more bioactive formulation of previously FDA-approved ONTAK®. The PDUFA target action date is September 28, 2023. The BLA is supported by a pivotal Phase 3 study (NCT01871727). 

Key Points: 
  • "The acceptance of the previously announced BLA submission for I/ONTAK is another important regulatory milestone for our oncology program.
  • I/ONTAK, a purified version of denileukin diftitox, is a reformulation of previously FDA-approved oncology treatment ONTAK.
  • The new formulation received regulatory approval in Japan in 2021 for the treatment of CTCL and peripheral T-cell lymphoma (PTCL).
  • Cutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma.

InventHelp Inventor Develops Toilet Paper Plus (LVT 439)

Retrieved on: 
Wednesday, November 23, 2022
Multimedia, PAPER, Sale, Hemorrhoid, Rash, Bacteria, Dry, Tissue paper, Publishing

PITTSBURGH, Nov. 22, 2022 /PRNewswire/ -- ""This is a newly modernized line of toilet paper rolls" said inventor from Las Vegas, NV "I wanted to create a cleaner and more sanitary way to wipe after using the bathroom."

Key Points: 
  • PITTSBURGH, Nov. 22, 2022 /PRNewswire/ -- ""This is a newly modernized line of toilet paper rolls" said inventor from Las Vegas, NV "I wanted to create a cleaner and more sanitary way to wipe after using the bathroom."
  • TOILET PAPER PLUS CONTATINER would help prevent irritations, hemorrhoids, bad odors, dryness, bacteria, and rashes.
  • This innovative design would consist of an all in one design., light weight, compact design, and help improve sanitary conditions.
  • The original design was submitted to the Los Vegas sales office of InventHelp.

Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program

Retrieved on: 
Monday, November 21, 2022
Transfer, Quality of life, Drug Quality and Security Act, IL-2R, CTCL, Tax, New Jersey Department of Health, PTCL, Fast Track, New Jersey Economic Development Authority, Immunotherapy, BLA, Net, Economic development, FDA, NOL, Treasury, Research, Patent, Annual report, Hemorrhoid, Pivotal, Patient, COVID-19, Risk, File, Regulation of tobacco by the U.S. Food and Drug Administration, Regulation, CGMP, State, Food, T-cell lymphoma, Peripheral T-cell lymphoma, Health insurance, Pharmaceutical industry, Citius, Altius, Fortius

CRANFORD, N.J., Nov. 21, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the Company has been selected to participate in New Jersey's Technology Business Tax Certificate Transfer (NOL) Program, more commonly known as the Net Operating Loss (NOL) Program, and will receive $3.6 million in non-dilutive capital through the New Jersey Economic Development Authority (NJEDA). Citius expects to receive the funds by late 2022 or early 2023.

Key Points: 
  • "This was the first year that Citius qualified for the program, and we are delighted to have been selected to participate in New Jersey's NOL Program.
  • We are thankful to the NJ Economic Development Authority for aiding our efforts in our initial year of participation.
  • The average award for companies approved to sell their net operating losses through the program in 2022 was over $3.1 million.
  • The New Jersey Economic Development Authority (NJEDA) serves as the State's principal agency for driving economic growth.

Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Wednesday, November 9, 2022
Food, File, Poster, Peripheral T-cell lymphoma, Diphtheria, U.S. Securities and Exchange Commission, Lymph, Hemorrhoid, FDA, Patient, SEC, Malignancy, Company, NHL, MF, T-cell lymphoma, CGMP, Fast Track, Haematopoietic system, City, Cancer, Immunotherapy, ODD, Securities Exchange Act of 1934, Drug Quality and Security Act, SS, Immune system, Disease, Mycosis fungoides, Cutaneous lymphoma, Forward-looking statement, BLA, IL-2R, PTCL, Interleukin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Man, Securities Act of 1933, Regulation, Protein, Pain, Pivotal, CA, Citius, Altius, Fortius, ASH, COVID-19, Woman, Itch, Research, Quality of life, Patent, Annual report, Safety, Pharmaceutical industry, Vaccine, CTCL

CRANFORD, N.J., Nov. 9, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced that abstracts for I/ONTAK (E7777) for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) have been accepted for presentations at the prestigious 64th American Society of Hematology (ASH) Annual Meeting, to be held in New Orleans, December 10-13, 2022.

Key Points: 
  • I/ONTAK is a recombinant fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments.
  • ONTAK was marketed in the U.S. from 1999 to 2014, when it was voluntarily withdrawn from the market.
  • The new formulation received regulatory approval in Japan in 2021 for the treatment of CTCL and peripheral T-cell lymphoma (PTCL).
  • Cutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma.

Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022

Retrieved on: 
Thursday, October 6, 2022
PTCL, Grand Hotel, Peripheral T-cell lymphoma, Citius, Altius, Fortius, Hemorrhoid, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, Multimedia, Pivotal, Food, T-cell lymphoma, IL-2R, Company, CTCL, BLA, Immunotherapy, Fast Track, FDA, Pharmaceutical industry

Wyndham Grand Hotel in Jupiter, Florida

Key Points: 
  • Wyndham Grand Hotel in Jupiter, Florida
    To request a meeting, please contact your Dawson James representative.
  • I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL).
  • In the first half of 2022, Citius initiated a Phase 2b trial for Halo-Lido, a topical formulation for the relief of hemorrhoids.
  • The Company anticipates completing enrollment in the Halo-Lido trial by the end of 2022.

Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Retrieved on: 
Wednesday, September 28, 2022
Pivotal, Securities Exchange Act of 1934, Lymph, Peripheral T-cell lymphoma, Woman, MF, PTCL, Biologics license application, FDA, COVID-19, Food, Drug Quality and Security Act, Malignancy, CGMP, NHL, Company, T-cell lymphoma, Hemorrhoid, Haematopoietic system, Securities Act of 1933, SS, Protein, Immunotherapy, Forward-looking statement, Patient, File, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, U.S. Securities and Exchange Commission, CEO, Pain, Quality of life, Regulation, Annual report, Interleukin, Fast Track, IL-2R, Cutaneous lymphoma, Research, BLA, SEC, Man, Immune system, ODD, Patent, Diphtheria, Mycosis fungoides, Disease, Itch, Pharmaceutical industry, Vaccine, CTCL, Citius, Altius, Fortius

"The treatment of advanced cutaneous T-cell lymphoma remains a complex and challenging unmet medical need.

Key Points: 
  • "The treatment of advanced cutaneous T-cell lymphoma remains a complex and challenging unmet medical need.
  • Each year, thousands of patients are diagnosed with CTCL, a debilitating orphan disease with no single standard of care.
  • "The BLA filing for denileukin diftitox marks the first of our pipeline candidates to be submitted for FDA approval."
  • I/ONTAK, a purified version of denileukin diftitox, is a reformulation of previously FDA-approved oncology treatment ONTAK.

Citius Pharmaceuticals, Inc. and its CFO & CBO Jaime Bartushak Honored by Somerset Hills Learning Institute

Retrieved on: 
Thursday, September 15, 2022
Pivotal, Institute, The Institute, Time, Somerset Hills, Peripheral T-cell lymphoma, PTCL, FDA, CTCL, Literature, Food, Company, T-cell lymphoma, Hemorrhoid, The Grove, Immunotherapy, Golf, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Brother, Student, Family, Science, Fast Track, IL-2R, School, Research, BLA, Education, Citius, Altius, Fortius, Autism, Pharmaceutical industry, Fireworks

CRANFORD, N.J. , Sept. 15, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Citius, along with the Company's Chief Financial Officer and Chief Business Officer, Jaime Bartushak, were named as 2022 Honorees by the Somerset Hills Learning Institute ("The Institute").  

Key Points: 
  • "The Institute is a very special place that has benefited my entire family immeasurably.
  • I am deeply honored to be recognized along with Citius as the 2022 Honorees," stated Bartushak.
  • Founded in 1998, Somerset Hills Learning Institute is a private nonprofit program that offers a broad spectrum of services to children, adolescents, and adults with autism.
  • In the first half of 2022, Citius initiated a Phase 2b trial for Halo-Lido, a topical formulation for the relief of hemorrhoids.

Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Thursday, September 8, 2022
BLA, Hemorrhoid, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PTCL, Food, CTCL, Multimedia, IL-2R, Fast Track, Immunotherapy, Company, FDA, Pivotal, Lotte New York Palace Hotel, T-cell lymphoma, Peripheral T-cell lymphoma, Citius, Altius, Fortius, Patient, Pharmaceutical industry

CRANFORD, N.J., Sept. 8, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), today announced that Citius will participate in the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022. Leonard Mazur, Chairman and CEO of Citius, will present in person on September 12, 2022 at 8:30 am EDT, and host one-on-one meetings with investors.

Key Points: 
  • Mino-Lokwas granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
  • I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL).
  • In the first half of 2022, Citius initiated a Phase 2b trial for Halo-Lido, a topical formulation for the relief of hemorrhoids.
  • The Company anticipates completing enrollment in the Halo-Lido trial by the end of 2022.